SCHEMBL6081

SCHEMBL6081

Cc1ccc(CCN)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 10/20 1.00
CYP2A6 P11509 2/20 1.00
CYP1A2 P05177 1/20 1.00
HTR2A P28223 4/20 0.56
BACE1 P56817 2/20 0.56
KDM4E B2RXH2 1/20 0.56
ALDH1A1 P00352 1/20 0.56
HTR1A P08908 1/20 0.56
ADRA2A P08913 1/20 0.56
SLC6A2 P23975 1/20 0.56
CYP2C19 P33261 1/20 0.56
HTR3A P46098 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
LOXL2 Q9Y4K0 2/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
BLM P54132 1/20 0.54
KMT2A Q03164 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
NOS3 P29474 1/20 0.50
NOS1 P29475 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL22160586 0.97 TAAR1 (0.95) TAAR1CYP2A6CYP1A2HTR2ABACE1
SCHEMBL11178971 0.97 TAAR1 (0.95) TAAR1CYP2A6CYP1A2HTR2ABACE1
Bromide SCHEMBL31206930 0.97 TAAR1 (0.95) TAAR1CYP2A6CYP1A2HTR2ABACE1
Iodide SCHEMBL28805530 0.97 TAAR1 (0.95) TAAR1CYP2A6CYP1A2HTR2ABACE1
SCHEMBL9468411 0.93 TAAR1 (0.86) TAAR1CYP2A6CYP1A2HTR2ABACE1
SCHEMBL8356905 0.93 TAAR1 (0.86) TAAR1CYP2A6CYP1A2HTR2ABACE1
SCHEMBL25131498 0.89 TAAR1 (0.78) TAAR1CYP2A6CYP1A2HTR2ABACE1
SCHEMBL12788471 0.87 TAAR1 (0.75) TAAR1CYP2A6CYP1A2BACE1ALDH1A1
SCHEMBL13710873 0.87 TAAR1 (0.75) TAAR1CYP2A6CYP1A2BACE1NOS3
SCHEMBL224548 0.85 TAAR1 (0.72) TAAR1CYP2A6CYP1A2HTR2ABACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1540 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250387385-A1 TREATMENT FOR GLOMERULAR DISEASES ZYDUS LIFESCIENCES LIMITED (IN) 2025-12-25 US claimed
EP-4565233-A1 TREATMENT FOR APLASTIC ANEMIA (AA) Zydus Lifesciences Limited (IN) 2025-06-11 EP claimed
EP-4549616-A1 PROCESS FOR MAKING AMINES FROM CARBONYL COMPOUNDS USING HYDROGEN HAVING LOW DEUTERIUM CONTENT PRODUCED WITH NON-FOSSIL ENERGY BASF SE (DE) 2025-05-07 EP claimed
EP-4539934-A1 TREATMENT FOR GLOMERULAR DISEASES Zydus Lifesciences Limited (IN) 2025-04-23 EP claimed
CN-119816306-A Treatment of Aplastic Anemia (AA) 载度思生命科学有限公司 2025-04-11 CN claimed
CN-119192880-A Preparation method of archaized pigment 江苏众立生包装科技有限公司 2024-12-27 CN claimed
US-20240199542-A1 SUBSTITUTED PYRROLIDIN-2-ONES, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES BAYER AKTIENGESELLSCHAFT (DE) 2024-06-20 US claimed
US-20240173314-A1 TREATMENT OF SICKLE CELL ANAEMIA ZYDUS LIFESCIENCES LTD. (IN) 2024-05-30 US claimed
CN-117886718-B Preparation method of high-selectivity asymmetric urea compound and asymmetric urea compound 内蒙古工业大学 2024-05-24 CN claimed
CN-117886718-A Preparation method of high-selectivity asymmetric urea compound and asymmetric urea compound 内蒙古工业大学 2024-04-16 CN claimed
US-5500428-A Furyl-substituted purines and adenosine antagonists IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1996-03-19 US claimed
US-5384170-A Multilayer element with thermoplastic polymers of polyvinyl alcohol and olefin copolymers NOVAMONT S.P.A. (IT) 1995-01-24 US claimed
WO-1994024095-A1 IMMUNOSUPPRESSIVE AGENTS ABBOTT LABORATORIES (US) 1994-10-27 WO claimed
US-5358851-A Polyclonal antibody from immunizing an animal with immunogenic carrier protein conjugated to p-tolylacetic acid, then binding product to the aromatic ring of benzene or naphthalene derivatives for detection QUANTIX SYSTEMS, L.P. (US) 1994-10-25 US claimed
US-5300509-A Adenosine antagonists for treating cardiovascular disorders, vasodilation IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1994-04-05 US claimed
EP-0544445-A2 Furyl-substituted purines, oxazolopyrimidines and pteridines as adenosine antagonists ZENECA LIMITED (GB) 1993-06-02 EP claimed
EP-0495950-A1 A LAMINATED FILM WITH A STARCHY MATRIX AND LOW PERMEABILITY AND METHODS FOR ITS PRODUCTION NOVAMONT S.p.A. (IT) 1992-07-29 EP claimed
WO-1992002363-A1 A LAMINATED FILM WITH A STARCHY MATRIX AND LOW PERMEABILITY AND METHODS FOR ITS PRODUCTION NOVAMONT S.P.A. (IT) 1992-02-20 WO claimed
EP-0321546-A1 IMMUNOASSAY FOR AROMATIC RING CONTAINING COMPOUNDS PECK, Dana P. (US) 1989-06-28 EP claimed
WO-1988009798-A1 IMMUNOASSAY FOR AROMATIC RING CONTAINING COMPOUNDS PECK DANA P (US) 1988-12-15 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199542-A1 SUBSTITUTED PYRROLIDIN-2-ONES, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES HPD, DDT, PPOX TAAR1 3744/4885CYP2A6 350/4885CYP1A2 44/4885
US-20250387385-A1 TREATMENT FOR GLOMERULAR DISEASES SSB, GRN, ALB TAAR1 4597/4885CYP2A6 4839/4885CYP1A2 4800/4885
US-20240173314-A1 TREATMENT OF SICKLE CELL ANAEMIA HBG1, HBB, HBG2 TAAR1 4317/4885CYP2A6 1617/4885CYP1A2 794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.